Bicycle Therapeutics reported their Q4 and full year 2019 financial results, highlighting a transformational year marked by a successful IPO and strengthened leadership, enabling effective execution of their pipeline development strategy. They also noted two new immuno-oncology collaborations aimed at expanding their portfolio of immune cell agonists.